The race bibs we wore always said, “I walk for Wilma Parnell,” my maternal grandmother, who died from breast cancer when my ...

The FDA grants priority review to AZN's sBLA for Enhertu to treat HER2-low or HER2-ultralow metastatic breast cancer. A ...

AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has ...

AstraZeneca and Daiichi Sankyo announced that their drug Enhertu (trastuzumab deruxtecan) has been granted Priority Review by the US FDA for trea ...

Enhertu improved the time it took for patients with a breast cancer subset to experience worsening pain and other symptoms, ...

AstraZeneca (AZN) and Daiichi Sanyko (DSKYF)(DSNKY) said the FDA has accepted their application with priority review for ...

With this year's Breast Cancer Awareness Month now underway, we are sharing eight facts and updates about breast cancer that ...

The health regulator has “missed an opportunity” to give women with advanced breast cancer a life-extending drug, a charity ...

As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...

Daiichi Sankyo has launched a new direct-to-consumer (DTC) campaign for Enhertu — the first DTC effort for its oncology unit ...

The sBLA is supported by results from the phase IIIDESTINY-Breast06 trial (NCT04494425), which showed that patients with HER2 ...